Galderma

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (April 2024) (Learn how and when to remove this message) This article may need to be rewritten to comply with Wikipedia's quality standards. You can help. The talk page may contain suggestions. (January 2025) This article may require copy editing for grammar, style, cohesion, tone, or spelling. You can assist by editing it. (January 2025) (Learn how and when to remove this message) (Learn how and when to remove this message)

Galderma S.A.

Company type	Public
Traded as	SIX: GALD
Industry	Dermatology Pharmaceuticals
Founded	In 1961 in Texas [1]
Headquarters	Zug, Switzerland
Key people	Flemming Ørnskov (CEO) Thomas Ebeling (chairman)
Revenue	US$4.08 billion (2023)[2]
Owner	Consortium led by EQT AB (2019–2024) Nestle (1981–2019) L'Oréal (1981–2014)
Number of employees	6,500 (2024)[2]
Website	galderma.com

Galderma SA is a Swiss domiciled pharmaceutical company specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oréal and Nestlé, it had been held by a consortium of private institutional investors since 2019, until IPO in 2024.

Galderma was formed in 1981 as a joint venture between Nestlé and L'Oréal, then it became a subsidiary of Nestlé.^[3] Since 2019, it belongs to an investment fund. The company, headed by president and CEO Flemming Ørnskov (ex-Shire), has 33 sites in 100 countries^[4] with a worldwide network of distributors and employs more than 4,600 people. The headquarters is based in Zug, Switzerland.